<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-success bg-green-100">
          Positive
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/IDEAYA-Biosciences-Inc-US45166A1025">IDEAYA Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Barrons</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.barrons.com/articles/ideaya-biosciences-stock-eye-cancer-therapy-trial-b5c3a0f1">Ideaya Biosciences Stock Jumps 15% on Eye Cancer Therapy Trial Results</a>
    </div>

      <div class="me-0 me-md-5">
        The California-based biotechnology company reports statistically significant results from a clinical trial evaluating its combination therapy for a rare eye cancer.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/IDEAYA-Biosciences-Inc-US45166A1025">IDEAYA Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-and-servier-announce-positive-topline-results-from-phase-23-registrational-trial-optimum-02-of-darovasertib-in-combination-with-crizotinib-in-first-line-hla-a0201-negative-metastatic-uveal-melanoma-302739905.html">IDEAYA Biosciences and Servier Announce Positive Topline Results from Phase 2/3 Registrational Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA-A*02:01-Negative Metastatic Uveal Melanoma</a>
    </div>

      <div class="me-0 me-md-5">
        Trial met the primary endpoint showing statistically significant improvement in median PFS by BICR, with 6.9 months for the darovasertib combination versus 3.1 months for ICT (HR: 0.42; 95% CI: 0.30, 0.59; p-value: 10,000 patients globally (including North America, Europe and Australia) and &gt;3,000 patients in the United States, with approximately 50% of patients progressing to metastatic diseas...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/IDEAYA-Biosciences-Inc-US45166A1025">IDEAYA Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-to-announce-topline-results-from-phase-23-optimum-02-trial-in-metastatic-uveal-melanoma-on-monday-april-13-2026-302739365.html">IDEAYA Biosciences to Announce Topline Results from Phase 2/3 OptimUM-02 Trial in Metastatic Uveal Melanoma on Monday, April 13, 2026</a>
    </div>

      <div class="me-0 me-md-5">
        SOUTH SAN FRANCISCO, Calif., April 10, 2026 /PRNewswire/ -- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company, today announced plans to issue a joint IDEAYA and Servier pre-market press release and host a conference call and webcast on Monday, April 13, 2026 at 8:00 a.m.
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/en/stock/IDEAYA-Biosciences-Inc-US45166A1025">IDEAYA Biosciences Inc</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">PRNewsWire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">6 months ago</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.prnewswire.com/news-releases/ideaya-biosciences-announces-first-patient-in-for-phase-1-trial-of-ide574-a-potential-first-in-class-dual-inhibitor-of-kat67-to-target-multiple-solid-tumor-indications-including-breast-prostate-crc-and-lung-cancer-302734096.html">IDEAYA Biosciences Announces First-Patient-In for Phase 1 Trial of IDE574, a Potential First-In Class Dual Inhibitor of KAT6/7 to Target Multiple Solid Tumor Indications, including Breast, Prostate, CRC, and Lung Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        Potential first-in-class and selective equipotent dual inhibitor of KAT6/7 with single-digit to low teens nano-molar cellular potency in target engagement assays against KAT6 and KAT7, and ~350-to-2,000-fold selectivity over the KAT5 and KAT8 paralogs KAT6/7 dual inhibitor demonstrates greater monotherapy efficacy and durability than KAT6 selective inhibitors in preclinical CDX and PDX models M...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/en/news/IDEAYA-Biosciences-Inc-US45166A1025/load_more?page=5">
      Show more News
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>